Nucana Plc (NCNA) has released an update.
NuCana plc, a clinical-stage biopharmaceutical company, has reported positive updates on its ProTide therapeutics, NUC-3373 and NUC-7738, showing promising efficacy and safety. The company has completed recruitment for a Phase 2 study on advanced colorectal cancer and anticipates a series of data readouts in 2024. With a solid cash position, NuCana aims to sustain its operations and advance its clinical programs into 2025.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.
